(Q32059557)

6 July 2017

1 reference

title

Pharmacokinetic optimisation of the treatment of neurocysticercosis (English)

1 reference

6 July 2017

1 reference

1 reference

Sotelo J

1

1 reference

PubMed ID

9646011

6 July 2017

Jung H

series ordinal

2

1 reference

6 July 2017

1 June 1998

1 reference

Clinical Pharmacokinetics

6 July 2017

1 reference

6 July 2017

34

1 reference

6 July 2017

6

1 reference

6 July 2017

503-515

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199834060-00006

6 July 2017

0 references

cites work

Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study.

1 reference

12 December 2020

Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis.

1 reference

12 December 2020

Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats

1 reference

12 December 2020

Pharmacokinetic comparison of two albendazole dosage regimens in patients with neurocysticercosis.

1 reference

12 December 2020

Intramedullary cysticercosis cured with drug treatment. A case report.

1 reference

12 December 2020

[Late results in the treatment of cerebral cysticercosis using praziquantel]

1 reference

12 December 2020

Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis

1 reference

12 December 2020

Neurocysticercosis. An introduction with special emphasis on new developments in pharmacotherapy

1 reference

12 December 2020

Single-day praziquantel therapy for neurocysticercosis

1 reference

12 December 2020

Neurocysticercosis: regression of a fourth ventricular cyst with praziquantel

1 reference

12 December 2020

[Pharmacokinetics and urinary metabolism of albendazole in man]

1 reference

12 December 2020

Albendazole therapy for neurocysticercosis

1 reference

12 December 2020

Short course of albendazole therapy for neurocysticercosis

1 reference

12 December 2020

Dexamethasone increases plasma levels of albendazole

1 reference

12 December 2020

Therapy of parenchymal brain cysticercosis with praziquantel.

1 reference

12 December 2020

Treatment of brain cysticercosis

1 reference

12 December 2020

Small intestinal sulphoxidation of Albendazole

1 reference

12 December 2020

Clinical pharmacokinetics of albendazole in patients with brain cysticercosis.

1 reference

12 December 2020

Treatment of experimental schistosomiasis mansoni with praziquantel alone and combined with cimetidine

1 reference

12 December 2020

Cysticercosis. Clinical classification based on imaging studies

1 reference

12 December 2020

Clinical pharmacokinetics of albendazole in children with neurocysticercosis.

1 reference

12 December 2020

A new shunt for hydrocephalus that relies on CSF production rather than on ventricular pressure: initial clinical experiences.

1 reference

12 December 2020

Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis.

1 reference

12 December 2020

Praziquantel in the cerebrospinal fluid in neurocysticercosis

1 reference

12 December 2020

Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients

1 reference

12 December 2020

Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis

1 reference

12 December 2020

Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants.

1 reference

12 December 2020

Albendazole as a potential treatment for human hydatidosis

1 reference

12 December 2020

Plasma levels of praziquantel decrease when dexamethasone is given simultaneously.

1 reference

12 December 2020

Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men.

1 reference

12 December 2020

Serum concentrations and renal excretion in humans after oral administration of praziquantel — results of three determination methods —

1 reference

12 December 2020

Short course albendazole treatment for neurocysticercosis in Columbia

1 reference

12 December 2020

Praziquantel in the treatment of neurocysticercosis: long-term follow-up.

1 reference

12 December 2020

Large cerebral infarction during praziquantel therapy in neurocysticercosis.

1 reference

12 December 2020

High-dose praziquantel for neurocysticercosis: serum and CSF concentrations.

1 reference

12 December 2020

Clinical pharmacokinetics of praziquantel

1 reference

12 December 2020

Pharmacokinetics of albendazole in man

1 reference

12 December 2020

Albendazole: a new concept in the control of intestinal helminthiasis.

1 reference

12 December 2020

Phenytoin and carbamazepine decreased oral bioavailability of praziquantel

1 reference

12 December 2020

Metabolism of albendazole in cattle, sheep, rats and mice

1 reference

12 December 2020

Therapy for neurocysticercosis: a reappraisal.

1 reference

12 December 2020

Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial

1 reference

12 December 2020

High-dose praziquantel for neurocysticercosis: efficacy and tolerability

1 reference

12 December 2020

[A case of successfully treated cerebral cysticercosis]

1 reference

12 December 2020

Neurocysticercosis: optimal dose treatment with albendazole

1 reference

12 December 2020

Therapy for neurocysticercosis. Comparison between albendazole and praziquantel

1 reference

12 December 2020

Drugs five years later: praziquantel

1 reference

12 December 2020

The course of seizures after treatment for cerebral cysticercosis

1 reference

12 December 2020

Increased systemic availability of albendazole when taken with a fatty meal

1 reference

12 December 2020

Albendazole treatment of echinococcosis in humans: effects on microsomal metabolism and drug tolerance

1 reference

12 December 2020

Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease

1 reference

12 December 2020

Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel.

1 reference

12 December 2020

Albendazole therapy for subarachnoid and ventricular cysticercosis. Case report

1 reference

12 December 2020

Failure of medical treatment in two cases of of intraocular cysticercosis

1 reference

12 December 2020

Treatment of neurocysticercosis with a two week course of albendazole.

1 reference

12 December 2020

Medical treatment of cysticercosis--ineffective

1 reference

12 December 2020

Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics

1 reference

12 December 2020

A correlation of toxicity of albendazole and oxfendazole with their free metabolites and bound residues

1 reference

12 December 2020

Albendazole therapy for giant subarachnoid cysticerci

1 reference

12 December 2020

Penetration of praziquantel into cerebrospinal fluid and cysticerci in human cysticercosis

1 reference

12 December 2020

Pharmacokinetics of albendazole in sheep

1 reference

12 December 2020

Therapy for Neurocysticercosis

1 reference

12 December 2020

Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial

1 reference

12 December 2020

Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen

1 reference

12 December 2020

Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle.

1 reference

12 December 2020

10.2165/00003088-199834060-00006

Identifiers

DOI

1 reference

PubMed ID

9646011

Dimensions Publication ID

6 July 2017

0 references

1 reference

PubMed ID

9646011